Skip to content Skip to footer
Subscribe Now
Viewpoints_Mark Genovese 
VIEWPOINTS

Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

Shots:  Recently, at UEGW 2024, Lilly presented histologic and combined histologic-endoscopic outcomes from the VIVID-1 Phase III study, which evaluated the safety and efficacy of mirikizumab in adults with moderately to severely active Crohn’s disease  A key finding reported during UEG Week highlighted the interactions between mirikizumab and ustekinumab, particularly regarding histologic response and remission,…
December 18, 2024

Read more

VIEWPOINTS_Robert Barrow_2023
VIEWPOINTS

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

Shots: Robert spoke about the topline data from the P-II study evaluating Lysergide. The data was unleashed by MindMed collaborators at the University Hospital Basel and the University Hospital of Psychiatry The data demonstrated significant, rapid, durable and beneficial effects of Lysergide and its potential to mitigate symptoms of MDD.  He also discussed how these…
August 29, 2023

Read more